KTRA - Rasio rega marang prakiraan pendapatan Kintara Therapeutics, Inc.

Kintara Pharma (KTRA) - logo korporat

Demand for unique treatments for aggressive brain tumors is creating significant intrigue around Kintara Therapeutics (KTRA). This forward P/S chart for Kintara Therapeutics (KTRA) visualizes the volatility of market expectations, where captures the current value of the indicator. Growth potential is based on the rollout of VAL-083 for glioblastoma therapy. Business stability is guaranteed by a transparent US regulatory regime and the humanitarian status of the developments.

Kintara Therapeutics Inc - Prakiraan rega marang pendapatan KTRA (periode 04.07.2022 - 16.11.2026)

Rincian metrik komprehensif lan analitis Kintara Therapeutics, Inc. (KTRA)

- rega pasar lan target rega analis:
Analisis umum perusahaan:Kintara KTRA
Produk sing diprodhuksi kintara.com

Investors must evaluate the fundamental stability of the asset through the ratio of current market capitalization to projected sales volume. By analyzing the expected revenue multiple, one can identify risks of undervaluation or an overheated business, which is critical for Kintara Therapeutics (KTRA), as the absence of stable cash flows and a liquidity deficit during the restructuring period make future sales the sole basis for valuation.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte Corp. INCY|HUTCHMED Ltd (HCM) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Inhibrx Biosciences Inc INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharmaceuticals FENC|Multiplikator forward rega marang pendapatan HRTX (Heron)|NVCT (Nuvectis Pharma) - Rega forward marang dodolan|Coherus Biosciences - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Multiplikator Forward P/S|Rega forward marang dodolan BYSI (BeyondSpring Pharma)|BCAB: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep lixte.com (LIXT)|Rasio rega marang prakiraan pendapatan citiuspharma.com|CLRB: Rega forward marang dodolan|Multiplikator Forward P/S BLRX|Multiplikator Forward P/S Can-Fite (CANF)|Rasio rega marang prakiraan pendapatan Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Rega mangsa ngarep marang pendapatan|SLXN: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NuCana|CMRX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Multiplikator Forward P/S|KRON: Rega forward marang dodolan|Multiplikator Forward P/S ONCT|PRTG (Portage) - Rega forward marang dodolan